New boxed warnings of clot risk ordered for immune globulin by FDA

06/13/2013 | Medscape (free registration)

The FDA authorized additional warning over the use of human immune globulin products after new data strengthened the connection between such products and thrombosis risk. Drugmakers will have to put additional risk information on the products' current boxed warning labels, while a box warning should be added to the labels of intramuscular and subcutaneous human immune globulin products. Additional data on risk mitigation strategies will also be a requirement.

View Full Article in:

Medscape (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL